Skip to main content
Smart Investors Daily
AB

NASDAQ · ABCL

AbCellera Biologics Inc.

Healthcare · Biotechnology

$11.12

Down-$0.37 (-3.22%)

Updated Nov 17, 2026, 4:48 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.08B
P/E ratio
-7.37
Dividend yield
0.00%
52-week range
$3.22 – $15.02
Volume
2.47M
Avg. volume
4.11M

Price performance · ABCL

ABCL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

ABCL closed at $11.12 after 21 trading sessions, down 6.79% for the selected period.

Last close
$11.12
Period change
-6.79%
Period low
$11.12
Period high
$13.64
Daily close
View OHLC price history
ABCL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$11.23$11.44$11.03$11.122.47M
Nov 13, 2026$11.75$11.83$11.055$11.492.68M
Nov 12, 2026$11.62$12.005$11.242$11.623.16M
Nov 11, 2026$12.695$12.952$11.93$11.952.87M
Nov 10, 2026$12.265$12.96$11.9083$12.463.91M
Nov 9, 2026$11.90$12.74$11.682$12.503M
Nov 6, 2026$11.56$11.98$11.20$11.882.21M
Nov 5, 2026$11.88$11.88$10.76$11.134.15M
Nov 4, 2026$12.325$12.54$11.5305$12.282.67M
Nov 3, 2026$11.32$12.3259$11.28$12.182.5M
Nov 2, 2026$12.33$12.33$11.0525$11.123.04M
Oct 30, 2026$12.65$12.91$11.75$12.273.88M
Oct 29, 2026$13.41$13.86$13.02$13.082.62M
Oct 28, 2026$12.67$13.65$12.6537$13.643.06M
Oct 27, 2026$11.98$12.89$11.85$12.833.46M
Oct 26, 2026$12.02$12.415$11.78$12.083.04M
Oct 23, 2026$11.45$11.895$11.08$11.823.03M
Oct 22, 2026$11.985$12.23$11.205$11.374.28M
Oct 21, 2026$11.78$12.365$11.59$12.243.22M
Oct 20, 2026$11.65$11.945$11.41$11.714.26M
Oct 19, 2026$12.045$12.28$11.75$11.933.14M

Latest ABCL news

The latest Smart Investors Daily articles mentioning ABCL.

ABCL research

Overview

Company profile and research snapshot.

Company profile

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$20.17
Implied upside
—
Analysts
—
ABCL recent ratings
DateFirmRatingTarget
Nov 11, 2026StoneXBuy—
Nov 10, 2026StifelBuy—
Oct 12, 2026UBSBuy—
Sep 29, 2026JP MorganOverweight—
Sep 24, 2026Goldman SachsNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.